Ramy Rahmé

Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Journal of Clinical Oncology · 2021 · 268 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Germline DDX41 mutations define a significant entity within adult MDS/AML patients

Marie Sébert, Marie Passet, Anna Raimbault et al. · Blood · 2019 · 209 citations

Life Sciences, Genetics, Molecular Genetics +16

Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia

Nabih Maslah, Norman Salomao, Louis Drevon et al. · Haematologica · 2019 · 139 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

Edmond Chiche, Ramy Rahmé, Sarah Bertoli et al. · Blood Advances · 2021 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Blood · 2019 · 65 citations

Medicine, Oncology, Pharmacotherapy +16